Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

Completed

Conditions: Histiocytic Disorders
Erdheim-Chester Disease
Langerhans Cell Histiocytosis

Interventions: Radiation: F-choline PET Scan
Device: FDG-PET
Procedure: biopsy

First Posted Date: 2015-11-20

Last Posted Date: 2018-08-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT02608619

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, New York, New York, United States

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Not Applicable

Completed

Conditions: Neuroendocrine Tumors

Interventions: Device: PET/CT Imaging
Radiation: 68Ga-DOTA-JR11
Radiation: 177Lu-DOTA-JR11

First Posted Date: 2015-11-20

Last Posted Date: 2022-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT02609737

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer (MBC)

Interventions: Drug: Palbociclib
Drug: Bicalutamide

First Posted Date: 2015-11-16

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 46

Registration Number: NCT02605486

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 2 locations

Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation

Completed

Conditions: Myelodysplastic Syndrome
Leukemia
Acute Myeloid Leukemia
Hematological Malignancy
Lymphoma
Myeloma

Interventions: Other: Symptom-limited cardiopulmonary exercise test (CPET)
Other: Resting assessment of cardiac function by echocardiography
Other: Post-exercise assessment of cardiac function by echocardiography
Other: Pulmonary function
Behavioral: Patient-reported outcomes questionnaire

First Posted Date: 2015-11-06

Last Posted Date: 2020-04-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT02598752

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps

Completed

Conditions: Head and Neck Cancer

Interventions: Other: physical exam
Behavioral: questionnaires

First Posted Date: 2015-10-09

Last Posted Date: 2019-08-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT02572869

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)

Completed

Conditions: Head and Neck Cancer

Interventions: Behavioral: Assessments

First Posted Date: 2015-10-08

Last Posted Date: 2024-04-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 65

Registration Number: NCT02571673

Locations: 🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2

Active, not recruiting

Conditions: Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma (DLBCL)
Relapsed Diffuse Large B-cell Lymphoma (DLBCL)

Interventions: Procedure: leukapheresis
Drug: Plerixafor
Drug: carmustine, etoposide, cytarabine, melphalan
Procedure: Autologous Stem Cell Transplantation

First Posted Date: 2015-10-07

Last Posted Date: 2024-11-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT02570542

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Consent and Follow-up Only), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Columbia University, New York, New York, United States

and more 11 locations

Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

Completed

Conditions: Colorectal Cancer
Breast Cancer
Lung Cancer

Interventions: Behavioral: Focus groups

First Posted Date: 2015-10-01

Last Posted Date: 2020-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 70

Registration Number: NCT02565017

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Not Applicable

Completed

Conditions: Metastatic Breast Cancer

Interventions: Radiation: Brain radiotherapy or Stereotactic Radiosurgery
Drug: Tremelimumab
Drug: HER2 directed therapy
Drug: Durvalumab

First Posted Date: 2015-09-30

Last Posted Date: 2022-08-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT02563925

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: 68Ga-RM2 (RM2)
Device: PET/CT Scan

First Posted Date: 2015-09-24

Last Posted Date: 2021-05-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT02559115

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy